Nanoparticle-Based Theranostics and Targeted Delivery for Cancer
This community develops nanomaterials and delivery systems to treat cancer, combining drug transport with imaging and physical therapies like photothermal and photodynamic treatment.
The work centers on engineering nanoparticles—often gold, lipid-based, or metal-organic frameworks—to deliver drugs and genetic material to specific tumor sites. A major focus is "theranostics," where the same platform facilitates diagnosis and treatment simultaneously. Recurring methods include photothermal therapy, which uses heat to kill cells, and photodynamic therapy, which activates light-sensitive agents. The research also heavily features chemodynamic therapy, which leverages reactive oxygen species to damage cancer cells, and immunotherapy strategies that modulate the tumor microenvironment. Specific applications target breast, lung, and colorectal cancers, as well as glioblastoma, with an emphasis on overcoming drug resistance and enhancing the efficacy of radiation and chemotherapy.
The community is most prominent in research tracked for oxygen, representing 0.9% of that element's literature, and gold, accounting for 1.1% of gold research. It also holds a significant share of platinum research at 0.9%. With 38,614 papers in total, the work is primarily published in the International Journal of Nanomedicine, Pharmaceutics, and ACS Nano.
Recent papers continue to focus on clinical translation of nanoparticle formulations, strategies to convert "cold" tumors into "hot" ones for immunotherapy, and the use of AI to drive nanomedicine design. Newer studies also explore brain-targeted delivery for neurodegenerative diseases and the use of ultrasound-responsive nanomaterials to induce cell death.